Cris S. Constantinescu

British Journal of Pharmacology · 2011

A researcher in the Science corpus: 1 paper; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Whom Cris S. Constantinescu trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. M. Feldmann

Papers from Cris S. Constantinescu's perspective

Ordered by how strongly the researchers Cris S. Constantinescu trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Multiple Sclerosis (Journal - Michigan State Medical Society)
  2. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. (American Journal of Pathology)
  3. Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages (Nature Immunology)
  4. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. (New England Journal of Medicine)
  5. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis (Annals of Neurology)
  6. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand (Nature Medicine)
  7. A controlled trial of natalizumab for relapsing multiple sclerosis. (New England Journal of Medicine)
  8. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
  9. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins (Nature)
  10. Development of anti-TNF therapy for rheumatoid arthritis (Nature reviews. Immunology)

Their papers